<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied a retrospective cohort of 282 higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, including 32 patients who concomitantly received an ESA for a median of 5.8 months after <z:chebi fb="0" ids="2038">azacitidine</z:chebi> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-four percent of ESA and 29% of no-ESA patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01) </plain></SENT>
<SENT sid="2" pm="."><plain>Median OS was 19.6 months in the ESA and 11.9 months in the no-ESA groups (p=0.04) </plain></SENT>
<SENT sid="3" pm="."><plain>Addition of an ESA significantly improved OS (p=0.03) independently of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> schedule and duration, and of our proposed <z:chebi fb="0" ids="2038">azacitidine</z:chebi> risk score (Blood 2011;117:403-11) </plain></SENT>
<SENT sid="4" pm="."><plain>Adding an ESA to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be studied prospectively </plain></SENT>
</text></document>